Article Text

Download PDFPDF

Response to: “How to communicate in science” by Klareskog et al
  1. René Toes1,
  2. David S Pisetsky2
  1. 1Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  2. 2Medicine, Medical Research Service, Durham, North Carolina, USA
  1. Correspondence to Dr René Toes, Rheumatology, Leiden University Medical Center, Leiden 2333 ZA, The Netherlands; r.e.m.toes{at}lumc.nl

Statistics from Altmetric.com

We have read with interest the reply by Klareskog et al, ‘How to communicate in science’,1 to our editorial, ‘Pathogenic effector function of ACPA: where do we stand?’.2 We agree with the authors that further studies are needed to elucidate the potential contributions of anticitrullinated protein antibodies (ACPAs) to the signs and symptoms of rheumatoid arthritis. We think that the effector functions of ACPAs is an exciting area of investigation and that these studies will provide important insights into disease pathogenesis and lead to new biomarkers to subtype patients, assess disease activity and monitor therapy.

References

View Abstract

Footnotes

  • Handling editor Josef S Smolen

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Correspondence
    Lars Klareskog Anca Irinel Catrina Camilla Svensson Vivianne Malmstrom